A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Thyroid Eye Disease (TED)
In brief
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Key facts
- Study ID
- NCT07211776
- Run by
- Zai Lab (Shanghai) Co., Ltd.
- People needed
- 99
- Starts
- 2025-12-05
- Expected to finish
- 2028-01-29
- Last updated by the study team
- 2025-12-29
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site01001 — Shanghai, China (enrolling)
- Site01008 — Foshan, China (enrolling)
- Site01004 — Fuzhou, China (enrolling)
- Site01007 — Guangzhou, China (enrolling)
- Site01027 — Guiyang, China (enrolling)
- Site01031 — Chongqing, China (enrolling)
- Site01002 — Hefei, China (enrolling)
- Site01024 — Jinan, China (enrolling)
- Site01005 — Luoyang, China (enrolling)
- Site01009 — Beijing, China (enrolling)
- Site01013 — Tianjin, China
- Site01016 — Wuxi, China
- Site01028 — Xi'an, China
- Site01025 — Xuzhou, China
- Site01026 — Yangzhou, China
- Site01019 — Zhengzhou, China
- Site01006 — Beijing, China
- Site01030 — Zhengzhou, China
- Site01010 — Beijing, China
- Site01029 — Bengbu, China
- Site01020 — Changsha, China
- Site01022 — Chengdu, China
- Site01011 — Dalian, China
- Site01018 — Hangzhou, China
- Site01017 — Nanchang, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.